Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally. It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded. The company also has a portfolio of wound management products, such as Hydrocyn Aqua, an antimicrobial solution and gel for improved wound healing; and surgical sutures comprising non-absorbable, natural absorbable, synthetic absorable, and specialty sutures. It has licensed partnership with Becton, Dickinson & Company for urinary catheter bardex IC and lubrisil IC; Well Lead Medical for catheters and tubes; and Zimmer Biomet for orthopedic trauma implants. The company was founded in 2005 and is headquartered in Stockholm, Sweden.
Metrics to compare | BACTIb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBACTIbPeersSector | |
---|---|---|---|---|
P/E Ratio | −39.1x | 0.0x | −0.5x | |
PEG Ratio | −0.50 | 0.00 | 0.00 | |
Price / Book | 3.0x | 0.0x | 2.6x | |
Price / LTM Sales | 3.9x | 0.0x | 3.0x | |
Upside (Analyst Target) | 66.7% | 0.0% | 52.5% | |
Fair Value Upside | Unlock | 0.0% | 8.7% | Unlock |